However, the same IVW analyses suggested an increased risk of developing gastric, hepatic, and oral cavity and pharyngeal cancers, and carcinoma in situ of the cervix uteri and endocervix associated with PCSK9 inhibitor use (OR = 1.44, 95%CI gastric cancer: 1.14~1.75, p = 1.88 × 10−2; OR = 1.99, 95%CIhepatic cancer: 1.46~2.53, p = 1.16 × 10−2; OR = 5.41, 95%CIoral cavity and pharyngeal cancer: 4.49~6.33, p = 3.36 × 10−4; OR = 5.84, 95%CICarcinoma in situ of cervix uteri: 4.56~7.12, p = 6.91 × 10−3, Figure 2). Here, PCSK9 is linked to gastric cancer.